Literature DB >> 35059115

Bifunctional Compounds as SMARCA2 Degraders for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 35059115      PMCID： PMC8762729          DOI： 10.1021/acsmedchemlett.1c00657

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.

Authors:  Aimo Kannt; Ivan Đikić
Journal:  Cell Chem Biol       Date:  2021-05-03       Impact factor: 8.116

Review 2.  Transforming targeted cancer therapy with PROTACs: A forward-looking perspective.

Authors:  William Farnaby; Manfred Koegl; Darryl B McConnell; Alessio Ciulli
Journal:  Curr Opin Pharmacol       Date:  2021-03-30       Impact factor: 5.547

Review 3.  Reviewing the toolbox for degrader development in oncology.

Authors:  Joel O Cresser-Brown; Graham P Marsh; Hannah J Maple
Journal:  Curr Opin Pharmacol       Date:  2021-05-28       Impact factor: 5.547

Review 4.  VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.

Authors:  Chao Wang; Yujing Zhang; Jie Wang; Dongming Xing
Journal:  Eur J Med Chem       Date:  2021-10-09       Impact factor: 6.514

Review 5.  Exploiting epigenetic dependencies in ovarian cancer therapy.

Authors:  Aisling Y Coughlan; Giuseppe Testa
Journal:  Int J Cancer       Date:  2021-08-06       Impact factor: 7.316
  5 in total
  1 in total

Review 1.  Discovery of E3 Ligase Ligands for Target Protein Degradation.

Authors:  Jaeseok Lee; Youngjun Lee; Young Mee Jung; Ju Hyun Park; Hyuk Sang Yoo; Jongmin Park
Journal:  Molecules       Date:  2022-10-02       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.